COMPARISON

Corticorelin vs Lanreotide

3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.

Answer

Corticorelin is authorised or registered in 0 and Lanreotide in 9 of the 10 registers read. Corticorelin: No trial states a phase. Lanreotide: highest phase Phase 4 (after approval). 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

CorticorelinLanreotide
Registered trials
differs
39
clinicaltrials.gov · 2026-10-03
125
clinicaltrials.gov · 2026-10-03
FDA label
differs
Not checked
no record of "fdaLabel" for corticorelin
FDA-approved: Lanreotide Acetate
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectCorticorelinplaceboLanreotideplacebo
Diarrhoea--19.5%23.6%
Abdominal pain--16.8%15.9%
Fatigue--12.2%14.6%
Nausea--11.0%12.0%
Vomiting--10.8%7.8%
Headache--10.7%9.4%
Hypertension--8.8%5.6%
Arthralgia--8.0%8.2%
Back pain--8.0%10.3%
Decreased appetite--8.0%8.6%

Trial register Corticorelin: 0 placebo-controlled trials; Lanreotide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Corticorelin side effects · Lanreotide side effects

LEGAL STATUS

Approval in each country read

CountryCorticorelinLanreotideRegister
United StatesNot on the registerFDA-approvedRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomNot on the registerAuthorisedRegulator MHRA
CanadaNot on the registerAuthorisedRegulator Health Canada
AustraliaStatus unknownRegistered TGA
SwitzerlandNot on the registerAuthorisedRegulator Swissmedic
BrazilNot on the registerRegistadoRegulator ANVISA
SerbiaNot on the registerAuthorisedRegulator ALIMS
SingaporeNot on the registerRegisteredRegulator HSA
TurkeyNot on the registerRuhsatliRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.